NAV

Selamectin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Selamectin
DrugBank Accession Number
DB11459
Background

Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats. It also removes 2 types of lungworm in cats and one type of lungworm in dogs. It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin. Selamectin is not approved for human use.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 769.973
Monoisotopic: 769.440111853
Chemical Formula
C43H63NO11
Synonyms
  • Selamectin
External IDs
  • UK 124114
  • UK-124,114
  • UK-124114
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Selamectin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Selamectin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Selamectin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Selamectin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Selamectin.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as milbemycins. These are a group of macrolides with a structure containing a 16-membered lactone ring fused to a 1,7-dioxaspiroundecane ring system and to either a benzofuran (or hydrogenated derivative thereof). In some cases (e.g. Milbemycin E), the tetrahydrofuranyl ring is missing. Milbemycins can be o-glycosylated at C13 to form Avermectins. Milbemycins are produced by Streptomyces species.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Milbemycins
Direct Parent
Milbemycins
Alternative Parents
O-glycosyl compounds / Ketals / Monosaccharides / Oxanes / Tertiary alcohols / Ketoximes / Tetrahydrofurans / Lactones / Carboxylic acid esters / Secondary alcohols
show 7 more
Substituents
Acetal / Alcohol / Aliphatic heteropolycyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether / Ether / Glycosyl compound / Hydrocarbon derivative
show 20 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
A2669OWX9N
CAS number
220119-17-5
InChI Key
AFJYYKSVHJGXSN-XHKIUTQPSA-N
InChI
InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35-,37-,38-,39-,40+,42+,43+/m0/s1
IUPAC Name
(1'R,2R,4'S,5S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'Z,24'S)-6-cyclohexyl-24'-hydroxy-12'-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-21'-(hydroxyimino)-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one
SMILES
[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O

References

General References
  1. Krautmann MJ, Novotny MJ, De Keulenaer K, Godin CS, Evans EI, McCall JW, Wang C, Rowan TG, Jernigan AD: Safety of selamectin in cats. Vet Parasitol. 2000 Aug 23;91(3-4):393-403. [Article]
  2. Novotny MJ, Krautmann MJ, Ehrhart JC, Godin CS, Evans EI, McCall JW, Sun F, Rowan TG, Jernigan AD: Safety of selamectin in dogs. Vet Parasitol. 2000 Aug 23;91(3-4):377-91. [Article]
  3. Gupta RC, Masthay MB, Canerdy TD, Acosta TM, Provost RJ, Britton DM, Atieh BH, Keller RJ: Human exposure to selamectin from dogs treated with revolution: methodological consideration for selamectin isolation. Toxicol Mech Methods. 2005;15(4):317-21. doi: 10.1080/15376520590968860. [Article]
  4. Jacobs DE: Selamectin - a novel endectocide for dogs and cats. Vet Parasitol. 2000 Aug 23;91(3-4):161-2. [Article]
  5. Shanks DJ, Gautier P, McTier TL, Evans NA, Pengo G, Rowan TG: Efficacy of selamectin against biting lice on dogs and cats. Vet Rec. 2003 Feb 22;152(8):234-7. [Article]
  6. Bishop BF, Bruce CI, Evans NA, Goudie AC, Gration KA, Gibson SP, Pacey MS, Perry DA, Walshe ND, Witty MJ: Selamectin: a novel broad-spectrum endectocide for dogs and cats. Vet Parasitol. 2000 Aug 23;91(3-4):163-76. [Article]
  7. Schnabl B, Bettenay S, Glos N, Linek M, Loewenstein C, Mueller RS: Oral selamectin in the treatment of canine generalised demodicosis. Vet Rec. 2010 Jun 5;166(23):710-4. doi: 10.1136/vr.4850. [Article]
  8. Dupuy J, Derlon AL, Sutra JF, Cadiergues MC, Franc M, Alvinerie M: Pharmacokinetics of selamectin in dogs after topical application. Vet Res Commun. 2004 Jul;28(5):407-13. [Article]
  9. Itoh N, Muraoka N, Aoki M, Itagaki T: Treatment of Notoedres cati infestation in cats with selamectin. Vet Rec. 2004 Mar 27;154(13):409. [Article]
  10. Mueller RS, Bettenay SV: Efficacy of selamectin in the treatment of canine cheyletiellosis. Vet Rec. 2002 Dec 21-28;151(25):773. [Article]
ChemSpider
16738655
RxNav
1044269
ChEMBL
CHEMBL1908325
ZINC
ZINC000169677006
Wikipedia
Selamectin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00425 mg/mLALOGPS
logP5.09ALOGPS
logP6.21Chemaxon
logS-5.3ALOGPS
pKa (Strongest Acidic)9.58Chemaxon
pKa (Strongest Basic)-3.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count11Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area154.73 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity206.75 m3·mol-1Chemaxon
Polarizability39.7 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fr-0000006900-15027f8419754a01d8e6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0100000900-575944fda7f6471eec62
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-0310009200-0696682435abd9d06844
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0100009300-d30e743d4e2d4fd0efaa
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-022i-1400009400-6d6a4e2d446aea7e2643
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0aor-3900006400-d786acbd7f40c9028de0
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-268.9271901
predicted
DarkChem Lite v0.1.0
[M-H]-259.0773
predicted
DeepCCS 1.0 (2019)
[M+H]+268.6380901
predicted
DarkChem Lite v0.1.0
[M+H]+260.73047
predicted
DeepCCS 1.0 (2019)
[M+Na]+268.5613901
predicted
DarkChem Lite v0.1.0
[M+Na]+266.88736
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 18:55 / Updated at February 21, 2021 18:53